SURPASS-2: Tirzepatide Beats Semaglutide for Blood Sugar and Weight Loss in Head-to-Head Trial
In a Phase 3 trial of 1,879 patients, tirzepatide at all doses was statistically superior to semaglutide 1mg for HbA1c reduction (up to -2.30% vs -1.86%) and produced up to 5.5 kg more weight loss over 40 weeks.
Quick Facts
What This Study Found
Tirzepatide was noninferior and superior to semaglutide 1mg: HbA1c reductions of -2.01%, -2.24%, -2.30% (5/10/15mg) vs -1.86% semaglutide. Weight loss differences: -1.9, -3.6, -5.5 kg favoring tirzepatide (all p<0.001).
Key Numbers
1,879 patients; HbA1c: -2.01/-2.24/-2.30% vs -1.86%; weight: -1.9/-3.6/-5.5 kg more; nausea 17-22% vs 18%; hypoglycemia 0.2-1.7% vs 0.4%; serious AEs 5-7% vs 3%
How They Did This
Open-label, 40-week, Phase 3 RCT (SURPASS-2). 1,879 patients randomized 1:1:1:1 to tirzepatide 5/10/15 mg or semaglutide 1 mg weekly. Primary endpoint: HbA1c change from baseline to 40 weeks. NCT03987919.
Why This Research Matters
This is the first head-to-head Phase 3 trial showing a new diabetes drug is superior to semaglutide — the previous best-in-class. It established tirzepatide as the most effective injectable for type 2 diabetes.
The Bigger Picture
SURPASS-2 marked a paradigm shift in diabetes treatment, establishing that dual GIP/GLP-1 receptor agonism produces better outcomes than GLP-1 alone. Tirzepatide (now marketed as Mounjaro) has since been approved for both diabetes and obesity.
What This Study Doesn't Tell Us
Open-label design (not blinded). Semaglutide dose was 1 mg (not the higher 2.4 mg dose used for weight management). Eli Lilly-funded. 40-week duration — longer-term comparisons needed. Serious adverse events slightly higher with tirzepatide (5-7% vs 3%).
Questions This Raises
- ?Would tirzepatide still be superior compared to semaglutide 2.4 mg?
- ?What drives tirzepatide's additional benefit — the GIP receptor activation, the dual mechanism, or both?
- ?Are the slightly higher serious adverse events with tirzepatide clinically meaningful?
Trust & Context
- Key Stat:
- -2.30% HbA1c vs -1.86% Tirzepatide 15mg reduced HbA1c by 0.45 percentage points more than semaglutide 1mg — a clinically and statistically significant difference (p<0.001)
- Evidence Grade:
- High evidence: large Phase 3 RCT with 1,879 patients, 40-week duration, and robust statistical methodology. Open-label design is the main limitation.
- Study Age:
- Published 2021. Tirzepatide has since been approved as Mounjaro (diabetes) and Zepbound (obesity). Additional data from SURPASS and SURMOUNT programs continues to accumulate.
- Original Title:
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Published In:
- The New England journal of medicine, 385(6), 503-515 (2021)
- Authors:
- Frías, Juan P(2), Davies, Melanie J(13), Rosenstock, Julio(10), Pérez Manghi, Federico C, Fernández Landó, Laura, Bergman, Brandon K, Liu, Bing, Cui, Xuewei, Brown, Katelyn
- Database ID:
- RPEP-05391
Evidence Hierarchy
Frequently Asked Questions
Is tirzepatide better than semaglutide?
In this trial, yes. Tirzepatide at all doses produced greater HbA1c reduction and weight loss than semaglutide 1mg. However, semaglutide was tested at 1mg, not the higher 2.4mg dose used for weight management. Both are effective medications with similar side effect profiles.
What is the difference between tirzepatide and semaglutide?
Semaglutide (Ozempic/Wegovy) activates only GLP-1 receptors. Tirzepatide (Mounjaro/Zepbound) activates both GIP and GLP-1 receptors simultaneously. This dual action appears to produce greater glucose control and weight loss.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05391APA
Frías, Juan P; Davies, Melanie J; Rosenstock, Julio; Pérez Manghi, Federico C; Fernández Landó, Laura; Bergman, Brandon K; Liu, Bing; Cui, Xuewei; Brown, Katelyn. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.. The New England journal of medicine, 385(6), 503-515. https://doi.org/10.1056/NEJMoa2107519
MLA
Frías, Juan P, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.." The New England journal of medicine, 2021. https://doi.org/10.1056/NEJMoa2107519
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide versus Semaglutide Once Weekly in Patients with ..." RPEP-05391. Retrieved from https://rethinkpeptides.com/research/frias-2021-tirzepatide-versus-semaglutide-once
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.